Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Discoid Excision Versus Segmental Resection for Rectal Endometriosis

14. November 2026 aktualisiert von: Ahmed Mohi Eldein, Alexandria University

Discoid/Double Discoid Excision Versus Segmental Resection for Rectal Deep Endometriosis Nodules <5 cm: A Randomized Controlled Trial of Bowel Complications and Functional Outcomes

This clinical trial will compare two types of surgery for endometriosis affecting the rectum, the lower part of the bowel. It will include 200 women aged 18 to 45 years who have symptoms and a single area of rectal endometriosis smaller than 5 cm. All participants must need surgery and be suitable for either procedure.

The main questions are:

Do the two procedures differ in the risk of bowel complications within 90 days after surgery?

How do the procedures affect bowel function, quality of life, and pain?

Participants will be assigned by chance to one of two groups:

Discoid or double discoid excision: The surgeon removes one or two overlapping discs of the affected bowel wall without removing an entire bowel segment.

Segmental resection: The surgeon removes the affected bowel segment and joins the remaining bowel ends.

Both procedures will be performed using keyhole surgery. Assignment will take place during surgery, after the surgeon confirms that either procedure is suitable.

Researchers will compare bowel complications, including leakage from the bowel closure, narrowing of the rectum, and abnormal connections between the bowel and nearby organs or tissues. Participants will complete questionnaires about quality of life and bowel function before surgery and at 6 and 12 months afterward. Researchers will also assess pain, recovery, and the need for further surgery. Follow-up will continue for up to 24 months to assess later symptoms and further treatment.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This prospective, single-center, parallel-group randomized controlled trial will compare bowel-preserving discoid or double discoid excision with segmental rectal resection for symptomatic rectal deep endometriosis. The study focuses on women with a single rectal nodule smaller than 5 cm for whom both surgical approaches are considered technically feasible.

The rationale is to determine whether removing only the affected portion of the rectal wall offers a different balance of postoperative bowel complications and functional outcomes compared with removal of the affected bowel segment. The discoid excision arm includes a double discoid technique when the lesion cannot be removed using a single stapler application.

Participants will provide written informed consent before surgery. Randomization will occur intraoperatively after laparoscopic assessment confirms nodule characteristics and eligibility for both procedures. A computer-generated sequence will allocate participants in a 1:1 ratio. Allocation will be concealed through a centralized online system accessed by an independent trial coordinator.

The discoid excision group will undergo laparoscopic mobilization of the rectum and full-thickness removal of the lesion using a circular stapler. Sequential double discoid excision will be used when required by lesion size. The segmental resection group will undergo laparoscopic removal of the affected bowel segment with a stapled colorectal anastomosis. Both groups will follow standardized protocols for bowel closure integrity testing, selective pelvic drainage, and indications for a diverting stoma. Conversion from the assigned technique will be permitted when intraoperative findings make it necessary for patient safety.

Surgeons and participants will not be blinded to treatment allocation. Postoperative outcome assessors, complication assessors, and the statistician performing the primary analysis will be blinded to allocation.

The primary comparison will assess the occurrence of the composite bowel complication outcome within 90 days after surgery. Longer-term assessments will examine bowel function, endometriosis-related quality of life, pain, symptom recurrence, and reintervention. Quality of life and bowel function will be measured using the Endometriosis Health Profile-30 questionnaire and the Low Anterior Resection Syndrome score.

The primary analysis will follow the intention-to-treat principle. Prespecified adjustment variables will include nodule size, circumferential involvement, and distance from the anal verge. Repeated questionnaire measurements will be analyzed using mixed-effects models. Treatment-effect estimates will be reported with 95% confidence intervals.

Studientyp

Interventionell

Einschreibung (Geschätzt)

200

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Alexandria, Ägypten
        • Rekrutierung
        • Alexandria University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 45 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Weiblich

Beschreibung

Inclusion Criteria:

  • Female participants aged 18 to 45 years.
  • Symptomatic deep infiltrating endometriosis involving the rectum, confirmed by transvaginal or transrectal ultrasonography or pelvic magnetic resonance imaging.
  • A single rectal endometriosis nodule measuring less than 5 cm in maximum diameter and amenable to discoid or double discoid excision.
  • Indication for surgical management following failure of, contraindication to, or patient refusal of medical therapy.
  • The nodule is considered by the surgical team to be technically suitable for both discoid or double discoid excision and segmental rectal resection, based on its size, circumferential extent, and distance from the anal verge. Suitability for both procedures must be confirmed laparoscopically before randomization.
  • Ability to provide written informed consent.
  • Ability to complete patient-reported outcome questionnaires and comply with follow-up.

Exclusion Criteria:

  • Rectal endometriosis nodule measuring 5 cm or larger in maximum diameter.
  • Rectal circumferential involvement exceeding 60%.
  • Multifocal bowel endometriosis.
  • Concurrent malignancy.
  • Inflammatory bowel disease.
  • Previous colorectal surgery.
  • Pregnancy.
  • Emergency presentation with bowel obstruction or perforation.
  • Inability to comply with follow-up or complete the required questionnaires.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Discoid or Double Discoid Excision

Participants will undergo laparoscopic full-thickness discoid excision of the rectal endometriosis nodule using a circular stapler. When the nodule exceeds the capacity of a single stapler application, sequential double discoid excision will be performed using two circular staplers. The procedure will remove the affected rectal wall without segmental bowel resection.

Laparoscopic mobilization of the rectum followed by full-thickness excision of the endometriosis nodule using a circular stapler. Sequential double discoid excision using two circular staplers will be performed when required by nodule size. An intraoperative air leak test will assess staple-line integrity. Pelvic drainage and a diverting stoma will be used selectively according to protocolized indications.

Aktiver Komparator: Segmental Rectal Resection

Participants will undergo laparoscopic resection of the bowel segment affected by rectal endometriosis, followed by a stapled end-to-end or end-to-side colorectal anastomosis. Mesorectal preservation close to the bowel wall will be used to limit disruption of the local blood supply.

Laparoscopic mobilization and resection of the affected bowel segment, followed by a stapled end-to-end or end-to-side colorectal anastomosis, with mesorectal preservation close to the bowel wall. An intraoperative air leak test will assess anastomotic integrity. Pelvic drainage and a diverting stoma will be used selectively according to protocolized indications.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants With Major Bowel-Related Complications
Zeitfenster: Within 90 days after surgery

Percentage of participants experiencing at least one of the following complications: anastomotic or staple-line leak, rectal stenosis, or rectovaginal or bowel fistula. Each participant will be counted once in the composite outcome, regardless of the number of qualifying complications. Complication severity will be graded using the Clavien-Dindo classification.

Within 90 days after surgery

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Operative Time
Zeitfenster: During surgery

Duration of the surgical procedure, measured in minutes.

During surgery
Percentage of Participants With Anastomotic or Staple-Line Leak
Zeitfenster: Within 90 days and within 12 months after surgery

Percentage of participants developing leakage from the colorectal anastomosis or rectal staple line following the assigned surgical procedure. Complication severity will be graded using the Clavien-Dindo classification.

Within 90 days and within 12 months after surgery
Percentage of Participants With Rectal Stenosis
Zeitfenster: Within 90 days and within 12 months after surgery

Percentage of participants developing postoperative narrowing at the rectal excision or colorectal anastomosis site. Complication severity will be graded using the Clavien-Dindo classification.

Within 90 days and within 12 months after surgery
Percentage of Participants With Rectovaginal or Bowel Fistula
Zeitfenster: Within 90 days and within 12 months after surgery

Percentage of participants developing an abnormal communication between the rectum and vagina, or another postoperative bowel fistula. Complication severity will be graded using the Clavien-Dindo classification.

Within 90 days and within 12 months after surgery
Endometriosis Health Profile-30 Domain Scores
Zeitfenster: Before surgery and at 6 and 12 months after surgery

Endometriosis-related quality of life assessed using the Endometriosis Health Profile-30 (EHP-30). The core questionnaire measures five domains: pain, control and powerlessness, emotional well-being, social support, and self-image. Each domain is scored separately from 0 to 100, with higher scores indicating worse health status. Domain scores will be compared between groups over time.

Before surgery and at 6 and 12 months after surgery
Low Anterior Resection Syndrome Score
Zeitfenster: Before surgery and at 6 and 12 months after surgery

Bowel function assessed using the Low Anterior Resection Syndrome (LARS) score, which evaluates incontinence for flatus, incontinence for liquid stools, bowel movement frequency, clustering, and urgency. Total scores range from 0 to 42, with higher scores indicating worse bowel dysfunction. Categories are no LARS (0-20), minor LARS (21-29), and major LARS (30-42). Scores will be compared between groups over time.

Before surgery and at 6 and 12 months after surgery
Estimated Intraoperative Blood Loss
Zeitfenster: During surgery

Estimated volume of blood lost during the surgical procedure, measured in milliliters.

During surgery
Postoperative Length of Hospital Stay
Zeitfenster: From surgery to discharge from the initial surgical hospitalization up to 1 week

Number of days from the surgical procedure to discharge from the hospital.

From surgery to discharge from the initial surgical hospitalization up to 1 week
Percentage of Participants Receiving a Diverting Stoma
Zeitfenster: During surgery

Percentage of participants undergoing creation of a diverting stoma during the assigned surgical procedure.

During surgery
Percentage of Participants With Recurrence of Endometriosis-Related Pain
Zeitfenster: At 12 and 24 months after surgery

Percentage of participants experiencing recurrence of endometriosis-related pain symptoms after initial postoperative improvement.

At 12 and 24 months after surgery

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

6. Oktober 2026

Primärer Abschluss (Geschätzt)

1. April 2027

Studienabschluss (Geschätzt)

1. Juli 2027

Studienanmeldedaten

Zuerst eingereicht

14. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. November 2026

Zuerst gepostet (Tatsächlich)

19. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

14. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 0308236

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .